-
,for, Item ID-
- #1064517
- Providers like you icon 280
- Glaxo Smith Kline #58160095509
Menveo® Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection 0.5 mL
MENVEO VACCINE, SDV 10-5MG/0.5ML (5/CT)
Features
- MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
- MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
- More …
Product Details Email
Product Specifications
| McKesson # | 1064517 |
|---|---|
| Manufacturer # | 58160095509 |
| Brand | Menveo® |
| Manufacturer | Glaxo Smith Kline |
| Country of Origin | Unknown |
| Application | Meningitis Vaccine |
| Buy American Act (BAA) Compliant | No |
| Container Type | Single-Dose Vial |
| Dosage Form | Injection |
| Generic Drug Code | 28272 |
| Generic Drug Name | Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free |
| NDC Number | 58160095509 |
| Product Dating | McKesson Acceptable Dating: we will ship >= 90 days |
| Storage Requirements | Requires Refrigeration |
| Strength | 10 mcg - 5 mcg / 0.5 mL |
| Trade Agreement Act (TAA) Compliant | No |
| Type | Intramuscular |
| UNSPSC Code | 51201610 |
| User | Indicated for People 2 Months to 55 Years of Age |
| Volume | 0.5 mL |
Features
- MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
- MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
More Information
Frequently Viewed Together
-
,for, Item ID-
- #772678
- Glaxo Smith Kline #58160084252
-
,for, Item ID-
- #1110687
- Sanofi Pasteur #49281040020
-
,for, Item ID-
- #1199151
- Pfizer (Non-COVID) #00005200010
-
,for, Item ID-
- #952614
- Merck #00006412102
-
,for, Item ID-
- #769341
- Glaxo Smith Kline #58160082152
-
,for, Item ID-
- #276842
- Merck #00006482700
-
,for, Item ID-
- #1238106
- Merck #00006468100
-
,for, Item ID-
- #1260442
- Pfizer #00409341411
-
,for, Item ID-
- #327341
- Sanofi Pasteur #49281086010
-
,for, Item ID-
- #1286786
- Glaxo Smith Kline #58160084952
-
,for, Item ID-
- #1102415
- Somerset Therapeutics LLC #70069002125
-
,for, Item ID-
- #562083
- Sanofi Pasteur #49281040010
-
,for, Item ID-
- #984817
- Merck #00006417100
-
,for, Item ID-
- #1047522
- Glaxo Smith Kline #58160097620
-
,for, Item ID-
- #723968
- Glaxo Smith Kline #58160081052
-
,for, Item ID-
- #772679
- Glaxo Smith Kline #58160082652